Nitric oxide and nitrovasodilators: Similarities, differences, and interactions

American Journal of Cardiology

Volumn 77, Issue 13, 1996, Pages C2-C7

  Kelly, Ralph A ^a   Smith, Thomas W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBACHOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; HYDRALAZINE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; MOLSIDOMINE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; NITROSO DERIVATIVE; ORGANIC NITRATE; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ANGINA PECTORIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; DRUG TRANSFORMATION; ENZYME ACTIVITY; HEART FAILURE; HEMODYNAMICS; HUMAN; INTRACORONARY INFUSION; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSDERMAL DRUG ADMINISTRATION; VASODILATATION;

HEART FAILURE, CONGESTIVE; HUMANS; NITRATES; NITRIC OXIDE; VASODILATOR AGENTS;

EID: 0029945944     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00182-8     Document Type: Article

References (70)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373.
2. Stamler JS. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 1994;78:931.
3. Harrison DG, Bates JN. The nitrovasodilators. New ideas about old drugs. Circulation 1993;87:1461.
4. Schmidt HHHW, Walter U. NO at work. Cell 1994;78:919.
5. Hare JM, Keaney JF Jr, Balligand J-L, et al. Role of nitric oxide in parasympathetic modulation of β-adrenergic myocardial contractility in normal dogs. J Clin Invest 1995;92:2198-2203.
6. Balligand J-L, Ungureanu-Longrois D, Simmons WW, et al. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. Characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem 1994;269:27580.
7. Balligand J-L, Kobzik L, Han X, et al. Nitric oxide-dependent parasympathetic signalling in cardiac myocytes is due to activation of type III (constitutive endothelial) NO synthase. J Biol Chem 1995;270:14582.
8. Nathan C, Xie Q-W. Nitric oxide synthases: roles, tolls, and controls. Cell 1994;78:915.
9. Risoe C, Simonsen S, Rootwelt K, et al. Nitroprusside and regional vascular capacitance in patients with severe congestive heart failure. Circulation 1992;85:997.
10. Kussmaul WG, Altschuler JA, Matthai WH, Laskey WK. Right ventricular-vascular interaction in congestive heart failure. Importance of low-frequency impedance. Circulation 1993;88:1010.
11. Heesch CM, Hatfield BA, Marcoux L, Eichhorn EJ. Predictors of pressure and stroke volume response to afterload reduction with nitroprusside in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 1994;74:951.
12. Fallen EL, Nahmias C, Scheffel A, et al. Redistribution of myocardial blood flow with topical nitroglycerin in patients with coronary artery disease. Circulation 1995;91:1381.
13. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3 Investigators: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115.
14. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669.
15. European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group. The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine. Lancet 1994;344:91.
16. Unger P, Vachiery J-L, de Canniere D, Staroukine M, Berkenboom G. Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure. Am Heart J 1994;128:557.
17. Conn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547.
18. Leier CV, Huss P, Magouin RD, Unverferth DV. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation 1983;67:817.
19. Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 1991;114:667.
20. Mangione NJ, Glasser SP. Phenomenon of nitrate tolerance. Am Heart J 1994;128:137.
21. Dupuis J. Nitrates in congestive heart failure. Cardiovasc Drugs Ther 1994;8:501.
22. Parker JD, Farrel B, Fenton T, Parker JO. Effect of diuretic therapy on the development of tolerance during continuous therapy with nitroglycerin. J Am Coll Cardiol 1992;20:612.
23. Dupuis J, Lalonde G, Bichet D, Rouleau JL. Captopril does not prevent nitroglycerin tolerance in heart failure. Can J Cardiol 1990;6:281.
24. Katz RJ, Levy WS, Buff L, Wasserman AG. Prevention of nitrate tolerance with angiotensin converting enzyme inhibitors. Circulation 1991;83:1271.
25. Dakak N, Makhoul N, Frugelman MY, et al. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:608.
26. Meredith IT, Alison JF, Zhang FM, et al. Captopril potentiates the effects of nitroglycerin in the coronary vascular bed. J Am Coll Cardiol 1993;22:581.
27. Metelitsa VI, Martesevich SY, Kozyreva MP, Slastnikova ID. Enhancement of the efficacy of isosorbide dinitrate by captopril in stable angina pectoris. Am J Cardiol 1992;69:291.
28. Parker JD, Parker JO. Effect of therapy with an angiotensin-converting enzyme inhibitor on hemodynamic and counter-regulatory responses during continuous therapy with nitroglycerin. J Am Coll Cardiol 1993;21:1445.
29. Ignarro L, Edwards J, Gruetter DY, et al. Possible involvement of S-nitrosothiols in the activation of guanylate cyclase by nitrous compounds. FEBS Lett 1980;110:275.
30. Munzel T, Mulsch A, Holtz J, et al. Mechanism of interaction between the sulfhydryl precursor L-methionine and glyceryl trinitrate. Circulation 1992;86:995.
31. May DC, Popma JJ, Black WH, et al. In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med 1987;317:805.
32. Parker JO, Farrel B, Lahey K, Rose BF. Nitrate tolerance: the lack of effect of N-acetyl cysteine. Circulation 1987;76:572.
33. Ghio S, de Servi S, Perotti R, et al. Different susceptibility to the development of nitroglycerin tolerance in the arterial and venous circulation in humans: effects of N-acetyl cysteine administration. Circulation 1992;86:798.
34. Munzel T, Holtz J, Mulsch A, et al. Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetyl cysteine in vivo, but tolerance-independent interactions exist. Circulation 1989;79:188.
35. Ghio S, Poli A, Ferrario M, et al. Hemodynamic effects of glyceryl trinitrate during continuous 24-hour infusion in patients with heart failure. Br Heart J 1994;72:145.
36. Mehra A, Shotan A, Ostrzega E, et al. Potentiation of isosorbide dinitrate effects with N-acetylcysteine in patients with chronic heart failure. Circulation 1994;89:2595.
37. Fung HL, Chong S, Lowaluk E, et al. Mechanisms for the pharmacologic interaction of organic nitrates with thiols: existence of an extracellular pathway for reversal of nitrate vascular tolerance by N-acetylcysteine. J Pharmacol Exp Ther 1988;245:524.
38. Boesgaard S, Aldershrile J, Poulsen HE. Preventive administration of intravenous N-acetylcysteine and development of tolerance to isosorbide dinitrate in patients with angina pectoris. Circulation 1992;85:143.
39. Munzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995;95:187.
40. Parker JD, Parker AB, Farrell B, Parker JO. Intermittent transdermal nitroglycerin therapy. Decreased anginal threshold during the nitrate-free interval. Circulation 1995;91:973.
41. Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Circulation 1995;91:1368.
42. Kobzik L, Reid MB, Bredt DS, Stamler JS. Nitric oxide in skeletal muscle. Nature 1994;372:546.
43. Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 1995;82:743.
44. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase: molecular cloning characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci USA 1992;88:6348.
45. Marletta MA. Nitric oxide synthase structure mechanism. J Biol Chem 1993;268:12231.
46. Han X, Shimoni Y, Giles WR. An obligatory role for nitric oxide in autonomic control of mammalian heart rate. J Physiol 1994;476:309.
47. Balligand J-L, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signalling system. Proc Natl Acad Sci USA 1993;90:347.
48. Kaye DM, Simmons WW, Balligand J-L, Kelly RA, Smith TW. Contractile activity activates a constitutive nitric oxide synthase in adult rat ventricular myocytes. Circulation 1994;90:I-33.
49. Ungureanu-Longrois D, Balligand J-L, Okada I, et al. Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease myocyte contractile responsiveness to β-adrenergic agonists. Circ Res 1995;77:494.
50. Balligand J-L, Ungureanu-Longrois D, Simmons WW, et al. Induction of NO synthase in rat cardiac microvascular endothelial cells by IL-1β and interferonγ. Am J Physiol 1995;268:H1293.
51. Roberts AB, Vodovotz Y, Roche NS, Sporn MB, Nathan CF. Role of nitric oxide in antagonistic effects of transforming growth factor-β and interleukin-1β on the beating rate of cultured cardiac myocytes. Mol Endocrinol 1992;6:1921.
52. Pfeilschifter J, Vosbeck K. Transforming growth factor beta 2 inhibits interleukin 1 beta- and tumor necrosis factor alpha-induction of nitric oxide synthase in rat renal mesangial cells. Biochem Biophys Res Commun 1991;175:372.
53. Vodovotz Y, Bogdan C, Paik J, Xie QW, Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor-β. J Exp Med 1993;178:605.
54. Singh K, Balligand J-L, Fischer TA, Smith TW, Kelly RA. Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells: role in regulation of inducible nitric oxide synthase (NOS2). J Biol Chem 1996;271:1111-1117.
55. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387.
56. Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest 1993;92:2303.
57. Werner ER, Werner-Felmayer G, Wachter H. Tetrahydrobiopterin and cytokines. Proc Soc Exp Biol Med 1993;203:1.
58. Gross SS, Levi R. Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. J Biol Chem 1993;268:25722.
59. Simmons WW, Balligand J-L, Ungureanu-Longrois D, et al. Dexamethasone regulates inducible nitric oxide synthase activity in cardiac microvascular endothelial cells by suppressing tetrahydrobiopterin synthesis. Circulation 1994;90:I-627.
60. Ungureanu-Longrois D, Balligand J-L, Okada I, et al. Contractile responsiveness of ventricular myocytes to isoproterenol by induction of nitric oxide synthase activity in cardiac microvascular endothelial cells in heterotypic primary culture. Circ Res 1995;77:486.
61. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109.
62. Garbers DL. Guanylyl cyclase receptors and their endocrine, paracrine, and autocrine ligands. Cell 1992;71:1.
63. Balligand J-L, Ungureanu-Longrois D, Kelly RA, et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 1993;91:2314.
64. Lange LG, Schreiner GF. Immune cytokines and cardiac disease. Trends Cardiovasc Med 1992;2:145.
65. Gulick TS, Chung MK, Pieper SJ, et al. Interleukin-1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad Sci USA 1989;86:6753.
66. Stamler JS, Simon DI, Osbome JA, et al. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 1992;89:444.
67. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci USA 1991;88:1197.
68. Schweizer M, Richter C. Nitric oxide potently and reversibly deenergizes mitochondria at low oxygen tension. Biochem Biophy Res Commun 1994;204:169.
69. Brown GC, Cooper CE. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett 1994;356:295.
70. Paulus WJ, Vantrimpont PJ, Shah, AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans: assessment by bicoronary sodium nitroprusside infusion. Circulation 1994;89:2070.